MCID: ATN005
MIFTS: 48

Autonomic Dysfunction

Categories: Blood diseases, Neuronal diseases

Aliases & Classifications for Autonomic Dysfunction

MalaCards integrated aliases for Autonomic Dysfunction:

Name: Autonomic Dysfunction 54
Autonomic Nervous System Disorders 72
Autonomic Disorder 55

Classifications:



External Ids:

UMLS 72 C1145628

Summaries for Autonomic Dysfunction

NINDS : 54 Dysautonomia refers to a disorder of autonomic nervous system (ANS) function that generally involves failure of the sympathetic or parasympathetic components of the ANS, but dysautonomia involving excessive or overactive ANS actions also can occur. Dysautonomia can be local, as in reflex sympathetic dystrophy, or generalized, as in pure autonomic failure. It can be acute and reversible, as in Guillain-Barre syndrome, or chronic and progressive. Several common conditions such as diabetes and alcoholism can include dysautonomia. Dysautonomia also can occur as a primary condition or in association with degenerative neurological diseases such as Parkinson's disease. Other diseases with generalized, primary dysautonomia include multiple system atrophy and familial dysautonomia. Hallmarks of generalized dysautonomia due to sympathetic failure are impotence (in men) and a fall in blood pressure during standing (orthostatic hypotension). Excessive sympathetic activity can present as hypertension or a rapid pulse rate.

MalaCards based summary : Autonomic Dysfunction, also known as autonomic nervous system disorders, is related to multiple system atrophy 1 and neuropathy, hereditary sensory and autonomic, type iia, and has symptoms including seizures, tremor and constipation. An important gene associated with Autonomic Dysfunction is ECE1 (Endothelin Converting Enzyme 1), and among its related pathways/superpathways are Neuroscience and Sympathetic Nerve Pathway (Neuroeffector Junction). The drugs Promethazine and Diphenhydramine have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and spinal cord, and related phenotypes are behavior/neurological and growth/size/body region

Wikipedia : 75 Dysautonomia or autonomic dysfunction is a condition in which the autonomic nervous system (ANS) does... more...

Related Diseases for Autonomic Dysfunction

Diseases related to Autonomic Dysfunction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 630)
# Related Disease Score Top Affiliating Genes
1 multiple system atrophy 1 32.3 SNCA DBH
2 neuropathy, hereditary sensory and autonomic, type iia 31.9 SCN9A RETREG1
3 perry syndrome 31.8 SNCA SLC18A2
4 pure autonomic failure 31.2 SNCA DBH
5 neuropathy, hereditary sensory and autonomic, type ic 31.1 SPTLC2 SPTLC1
6 peripheral nervous system disease 30.0 SPTLC1 SCN9A
7 movement disease 29.7 SNCA SLC18A2
8 parkinson disease, late-onset 29.7 SNCA SLC18A2 DBH
9 autonomic neuropathy 29.3 SPTLC2 SPTLC1 SCN9A RETREG1
10 neuropathy 29.0 SPTLC2 SPTLC1 SCN9A RETREG1
11 dementia, lewy body 28.9 SNCA SLC18A2
12 hirschsprung disease, cardiac defects, and autonomic dysfunction 12.8
13 pitt-hopkins syndrome 11.8
14 neuroleptic malignant syndrome 11.7
15 autosomal dominant leukodystrophy with autonomic disease 11.7
16 dysautonomia 11.5
17 lambert-eaton myasthenic syndrome 11.5
18 autonomic nervous system disease 11.4
19 spastic paraplegia 2, x-linked 11.3
20 parkinsonism-dystonia, infantile, 2 11.3
21 neuropathy, hereditary sensory and autonomic, type ia 11.1
22 paroxysmal extreme pain disorder 11.1
23 indifference to pain, congenital, autosomal recessive 11.1
24 neuronal intranuclear inclusion disease 11.1
25 parkinson disease 4, autosomal dominant 11.1
26 aromatic l-amino acid decarboxylase deficiency 11.1
27 sudden infant death with dysgenesis of the testes syndrome 11.1
28 neuropathy, hereditary sensory and autonomic, type iib 11.1
29 parkinson disease 5, autosomal dominant 11.1
30 striatonigral degeneration 11.1
31 brain dopamine-serotonin vesicular transport disease 11.1
32 opsoclonus-myoclonus syndrome 11.1
33 riboflavin transporter deficiency 11.1
34 myoclonic encephalopathy of infants 11.1
35 syncope 10.5
36 orthostatic intolerance 10.4
37 guillain-barre syndrome 10.4
38 polyneuropathy 10.4
39 multiple sclerosis 10.4
40 constipation 10.4
41 resting heart rate, variation in 10.4
42 cardiac conduction defect 10.3
43 impotence 10.3
44 sleep apnea 10.3
45 migraine with or without aura 1 10.3
46 sexual disorder 10.3
47 liver disease 10.3
48 scleroderma, familial progressive 10.3
49 diabetes mellitus 10.3
50 spinal cord injury 10.3

Graphical network of the top 20 diseases related to Autonomic Dysfunction:



Diseases related to Autonomic Dysfunction

Symptoms & Phenotypes for Autonomic Dysfunction

UMLS symptoms related to Autonomic Dysfunction:


seizures, tremor, constipation, vomiting, back pain, pain, headache, diarrhea, syncope, mydriasis, chronic pain, sciatica, vertigo/dizziness, sleeplessness, rectal tenesmus, increased sweating, decrease in appetite, vomiting alone, rectal pain, dry throat, hyperemesis, anal pain, vomiting in newborn, lightheadedness, warm skin, palpitations - fluttering, pounding heart, syncope, effort, blackout - symptom

MGI Mouse Phenotypes related to Autonomic Dysfunction:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.85 DBH RETREG1 SCN9A SLC18A2 SNCA SPTLC1
2 growth/size/body region MP:0005378 9.8 DBH ECE1 SCN9A SLC18A2 SNCA SPTLC2
3 integument MP:0010771 9.73 DBH ECE1 RETREG1 SCN9A SNCA SPTLC2
4 mortality/aging MP:0010768 9.7 DBH ECE1 SCN9A SLC18A2 SNCA SPTLC1
5 nervous system MP:0003631 9.5 DBH ECE1 RETREG1 SCN9A SLC18A2 SNCA
6 taste/olfaction MP:0005394 8.8 SCN9A SLC18A2 SNCA

Drugs & Therapeutics for Autonomic Dysfunction

Drugs for Autonomic Dysfunction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 257)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Promethazine Approved, Investigational Phase 4 60-87-7 4927
2
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
3
Zolpidem Approved Phase 4 82626-48-0 5732
4
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
5
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537
6
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
7
Levodopa Approved Phase 4 59-92-7 6047
8
Propranolol Approved, Investigational Phase 4 525-66-6 4946
9
Metronidazole Approved Phase 4 443-48-1 4173
10
Norepinephrine Approved Phase 4 51-41-2 439260
11
Droxidopa Approved, Investigational Phase 4 23651-95-8 443940
12
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
13
Mecamylamine Approved, Investigational Phase 4 60-40-2 4032
14 Dopamine Antagonists Phase 4
15 Tranquilizing Agents Phase 4
16 GABA Agents Phase 4
17 Hypnotics and Sedatives Phase 4
18 GABA Agonists Phase 4
19 GABA-A Receptor Agonists Phase 4
20 Dopamine agonists Phase 4
21 Dopamine Agents Phase 4
22 Anti-Arrhythmia Agents Phase 4
23 Anti-Bacterial Agents Phase 4
24 Anti-Infective Agents Phase 4
25 Antiparasitic Agents Phase 4
26 Antiprotozoal Agents Phase 4
27 Antiemetics Phase 4
28 Gastrointestinal Agents Phase 4
29 Adrenergic Agonists Phase 4
30 Adrenergic alpha-Agonists Phase 4
31 Pharmaceutical Solutions Phase 4
32 Antiparkinson Agents Phase 4
33 Serotonin Antagonists Phase 4
34 Serotonin Agents Phase 4
35 Cholinergic Agents Phase 4
36 Cholinergic Antagonists Phase 4
37
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
38
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
39
Metoclopramide Approved, Investigational Phase 3 364-62-5 4168
40
Methyldopa Approved Phase 3 555-30-6 38853
41
Carbidopa Approved Phase 3 28860-95-9 34359
42
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 23925 27284
43
Deferasirox Approved, Investigational Phase 3 201530-41-8 5493381
44 Sympathomimetics Phase 3
45 Parasympatholytics Phase 2, Phase 3
46 Antidepressive Agents, Second-Generation Phase 2, Phase 3
47 Muscarinic Antagonists Phase 2, Phase 3
48 Serotonin and Noradrenaline Reuptake Inhibitors Phase 2, Phase 3
49 Duloxetine Hydrochloride Phase 2, Phase 3
50 Cardiotonic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 210)
# Name Status NCT ID Phase Drugs
1 Inspiratory Muscle Training in Patients With Autonomic Neuropathic: a Randomized Trial Unknown status NCT00752440 Phase 4
2 Risperidone and Zotepine in the Treatment of Delirium Unknown status NCT00622011 Phase 4 Risperidone and Zolpidem for delirium
3 Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable Sensors Unknown status NCT03098368 Phase 4 Rotigotine;Placebo
4 Effect of Duodenal Levodopa Infusion on Quality of Life and Autonomic Dysfunction in Patients With Parkinson's Disease Completed NCT00914134 Phase 4 Levodopa infusion
5 Using Propranolol in Traumatic Brain Injury to Reduce Sympathetic Storm Phenomenon: A Prospective Randomized Clinical Trial Injury to Reduce Sympathetic Storm Phenomenon: A Prospective Randomized Clinical Trial Completed NCT03401515 Phase 4 Propranolol Hydrochloride 1 MG/ML
6 The Study of Heart Rate Variability in Patients With Fibromyalgia - Effects of Strengthening Exercises Completed NCT02004405 Phase 4
7 Efectividad de Saccharomyces Oulardii Para Reducir Los síntomas Gastrointestinales y Evitar el Sobrecrecimiento Bacteriano en Esclerosis sistémica Completed NCT03692299 Phase 4 Saccharomyces Boulardii Oral Tablet;Metronidazole
8 Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury Recruiting NCT03602014 Phase 4 Northera
9 Attenuation of Spinal Induced Hypotension With Granisetron in Type I Diabetic Parturients Recruiting NCT03091881 Phase 4 Granisetron 0.1 MG/ML;Placebos
10 Pilot Study of Mecamylamine for Autonomic Dysreflexia Prophylaxis Recruiting NCT03914677 Phase 4 Mecamylamine Oral Tablet
11 Safety and Efficacy of Orally Administered Fx-1006A in Patients With Familial Amyloid Polyneuropathy (FAP): A Randomized, Double-blind, Placebo-controlled Study Completed NCT00409175 Phase 2, Phase 3 Fx-1006A;Placebo
12 A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Subjects With Painful Diabetic Peripheral Neuropathy Completed NCT02427464 Phase 3
13 Effects of Escitalopram vs. Duloxetine on Heart Rate Variability and Autonomic Cardiovascular Control Completed NCT00215228 Phase 2, Phase 3 duloxetine vs. escitalopram
14 An Open-label Study, to Assess the Long-term Safety and Clinical Benefit of Droxidopa in Subjects With PAF, Dopamine Beta Hydroxylase Deficiency or Non-diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension Completed NCT00738062 Phase 3 Droxidopa;Placebo
15 Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH Completed NCT00633880 Phase 3 Placebo;Droxidopa
16 Phase III, Multi-Center, Study to Assess the Clinical Effect of Droxidopa in Subjects With Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic NOH Completed NCT00782340 Phase 3 Placebo;Droxidopa
17 Gut Microbiota Alteration and Improvement of Ataxia in Patients of Multiple System Atrophy Treating With Tllsh2910 - a Randomized, Placebo-controlled, Double-blinded, Cross-over, Single-center Clinical Trial Recruiting NCT03901638 Phase 3 Tllsh2910;Placebo
18 Treatment of Hypotensive Patients Having a Unique Pattern of Autonomic Symptoms Enrolling by invitation NCT00581477 Phase 3 droxidopa;placebo;alpha-methyldopa;carbidopa;metyrosine;levodopa;atomoxetine;metoclopramide
19 Clinical Importance of Treating Iron Overload in Sickle Cell Disease Terminated NCT00981370 Phase 3 deferasirox
20 The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy. Phase A: Breath Testing and Colonic Transit in Hepatic Encephalopathy. Phase B: A Randomized Double Blind, Placebo Controlled Trial of Rifaximin for Hepatic Encephalopathy Unknown status NCT00281502 Phase 2 Rifaximin (drug)
21 Evaluation à Six Mois du système de dénervation rénale Chez Les Patients Atteints d'Insuffisance Cardiaque Unknown status NCT02471729 Phase 1, Phase 2
22 Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins Completed NCT00750867 Phase 2 intravenous immunoglobulin (IVIg)
23 A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study of NNZ-2566 in Rett Syndrome Completed NCT01703533 Phase 2 NNZ-2566;Placebo
24 A Phase I/II, Open Label, Dose-Escalation Study to Assess the Safety and Tolerability of VM202 in Patients With Painful Diabetic Peripheral Neuropathy Completed NCT01002235 Phase 1, Phase 2
25 A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of the Safety and Pharmacokinetics of Oral NNZ-2566 in Pediatric Rett Syndrome Completed NCT02715115 Phase 2 NNZ-2566;Placebo
26 Daily Incorporation of Blueberries Into a Diet Favorably Improves Vascular Function and Lowers Aortic Blood Pressure in Postmenopausal Women With Pre- and Stage 1-hypertension. Completed NCT01686282 Phase 2
27 A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Subjects With Painful Diabetic Peripheral Neuropathy Completed NCT01475786 Phase 2
28 A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Three Doses of TAK-128 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy Completed NCT00229437 Phase 2 TAK-128;TAK-128;TAK-128;Placebo
29 Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure? Completed NCT00291720 Phase 2 Spironolactone;Placebo
30 A Phase II, Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Assess the Clinical Benefit and Safety of Droxidopa in Patients With Intradialytic Hypotension Completed NCT00657046 Phase 2 Droxidopa;Placebo
31 A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying Completed NCT01602549 Phase 2 GSK962040 (25 mg tablet);Placebo
32 A Phase 1 Clinical Study to Assess Safety and Efficacy of Oral Fingolimod (FTY720) in Children With Rett Syndrome. Completed NCT02061137 Phase 1, Phase 2 fingolimod (FTY720)
33 Effects of Oral L-citrulline/L-arginine in Watermelon on Central Blood Pressure and Arterial Stiffness in Individuals With Obesity-related High Blood Pressure Completed NCT01185041 Phase 1, Phase 2
34 Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome Completed NCT01607073 Phase 2 Verapamil
35 A Randomized, Double Blind, Placebo-controlled Crossover Study of Tolerability and Efficacy of Cannabidiol (CBD) on Tremor in Parkinson's Disease Completed NCT02818777 Phase 2 cannabidiol
36 Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy. Recruiting NCT03137537 Phase 2 Ivabradine;Placebo Oral Tablet
37 The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes Recruiting NCT03426085 Phase 2 Liraglutide 6 mg Solution for Injection
38 A Double-Blind, Randomized, Placebo-Controlled Trial To Evaluate The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes Recruiting NCT02915263 Phase 2 IGIV-C;0.9% Sodium Chloride
39 Left Cardiac Sympathetic Denervation (LCSD) for Cardiomyopathy Feasibility Pilot Study Recruiting NCT03071653 Phase 2
40 A Randomized, Double Blind, Placebo-controlled Parallel Study of Tolerability and Efficacy of Cannabidiol (CBD) on Motor Symptoms in Parkinson's Disease Recruiting NCT03582137 Phase 2 Cannabidiol
41 The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease Recruiting NCT03775096 Phase 2 Carvedilol
42 eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients Active, not recruiting NCT02458690 Phase 2 Antidepressant Medications
43 Inflammation Inhibition for Microvascular and Autonomic Dysfunction in Obese Prediabetic Humans Active, not recruiting NCT01977417 Phase 2 Salsalate;Placebo
44 Uncontrolled Pilot Trial of Transnasal Nicotine in Parkinson Disease Not yet recruiting NCT03865121 Phase 2 Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)
45 Controlled Trial of 3,4-Diaminopyridine in LEMS Terminated NCT02090725 Phase 2 3-4 Diaminopyridine
46 The Role of the "Inflammatory/ Pathogen Burden" for Cardiac Ageing Terminated NCT01045512 Phase 2 fluvastatin
47 An Open-Label, Multi-Center Study to Evaluate the Safety of Long-Term Administration of TAK-128 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy Terminated NCT00756041 Phase 2 TAK-128
48 Vagal Stimulation in POTS - The Autonomic Inflammatory Reflex (Pilot 3) Recruiting NCT03124355 Phase 1 placebo sugar pill;Pyridostigmine Pill;Galantamine Pill
49 The Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Aim 2 of RDCRN (Rare Diseases Clinical Research Network) Project 2 Recruiting NCT02897063 Phase 1 Droxidopa;Midodrine;Placebo
50 Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic Aim 1 of Rare Diseases Clinical Research Network (RDCRN) Project 2 Recruiting NCT02726711 Phase 1 Trimethaphan;Placebo

Search NIH Clinical Center for Autonomic Dysfunction

Genetic Tests for Autonomic Dysfunction

Anatomical Context for Autonomic Dysfunction

MalaCards organs/tissues related to Autonomic Dysfunction:

41
Heart, Testes, Spinal Cord, Brain, Liver, Skin, Kidney

Publications for Autonomic Dysfunction

Articles related to Autonomic Dysfunction:

(show top 50) (show all 5660)
# Title Authors PMID Year
1
Brainstem cholinergic pathways diminish cardiovascular and neuroinflammatory actions of endotoxemia in rats: Role of NFκB/α7/α4β2AChRs signaling. 38
31247270 2019
2
Glial α-synuclein promotes neurodegeneration characterized by a distinct transcriptional program in vivo. 38
31267577 2019
3
Autonomic impairment as a potential biomarker in idiopathic REM-sleep-behavior disorder. 38
31219036 2019
4
Changes in excitability and ion channel expression in neurons of the major pelvic ganglion in female type II diabetic mice. 38
31331692 2019
5
A comparison of the prevalence of orthostatic hypotension between older patients with Alzheimer's Disease, Lewy body dementia, and without dementia. 38
31173842 2019
6
Restless legs syndrome, periodic limb movements during sleep and cardiovascular risk. 38
31331694 2019
7
The association between obstructive sleep apnea during REM sleep and autonomic dysfunction as measured by heart rate variability. 38
30685848 2019
8
Clinical autonomic dysfunction in Narcolepsy Type 1. 38
31418025 2019
9
Low deceleration capacity is associated with higher stroke risk in patients with paroxysmal atrial fibrillation. 38
31433328 2019
10
A practical guide to active stand testing and analysis using continuous beat-to-beat non-invasive blood pressure monitoring. 38
31076939 2019
11
Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review. 38
31407119 2019
12
Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system. 38
31399774 2019
13
Tonic pupils: an unusual autonomic involvement in chronic inflammatory demyelinating polyneuropathy (CIDP). 38
30997592 2019
14
No common denominator: Plant-based diets and treatment-induced neuropathy of diabetes. 38
31371079 2019
15
Reactive Vasodilation Predicts Mortality in Primary Systemic Light Chain (AL) Amyloidosis. 38
31401949 2019
16
Utility of autonomic testing for the efficient diagnosis and effective pharmacological management of neurogenic orthostatic hypotension. 38
31434666 2019
17
Parkinson's disease with orthostatic hypotension: analyses of clinical characteristics and influencing factors. 38
31030628 2019
18
Autonomic dysfunction as measured by Ewing battery test to predict poor outcome after acute ischaemic stroke. 38
31416978 2019
19
Heme and sensory neuropathy: insights from novel mutations in the heme exporter FLVCR1. 38
31408049 2019
20
Heart rate variability as a predictor of rapid renal function deterioration in chronic kidney disease patients. 38
30328166 2019
21
Autonomic dysfunction in myalgic encephalomyelitis and chronic fatigue syndrome: comparing self-report and objective measures. 38
31115729 2019
22
Insular resection may lead to autonomic function changes. 38
31254846 2019
23
Resting pupil size is a predictor of hypotension after induction of general anesthesia. 38
31422468 2019
24
Ivabradine modulates the autonomic nervous system by affecting the "little brain" of the heart: A hypothesis. 38
31371087 2019
25
The inflammatory response to a wheelchair half-marathon in people with a spinal cord injury - the role of autonomic function. 38
30836837 2019
26
A model-based analysis of autonomic nervous function in response to the Valsalva maneuver. 38
31369335 2019
27
Cerebral lesion correlates of sympathetic cardiovascular activation in multiple sclerosis. 38
31403742 2019
28
Multiple system atrophy mimicked by multi-organ pathology. 38
30975708 2019
29
Quantitative autonomic function test in differentiation of multiple system atrophy from idiopathic Parkinson disease. 38
31373907 2019
30
Autonomic dysfunction in Parkinson disease and animal models. 38
30604165 2019
31
Effect of exercise training on heart rate variability in patients with obstructive sleep apnea: A randomized controlled trial. 38
31050034 2019
32
Orthostatic heart rate does not predict symptomatic burden in pediatric patients with chronic orthostatic intolerance. 38
31385108 2019
33
Children with orthostatic intolerance exhibit elevated markers of inflammation in the dorsal medulla. 38
31225987 2019
34
Diagnosis and Management of Autonomic Dysfunction in Dementia Syndromes. 38
31290049 2019
35
Fatigue in chronic hepatitis B patients is significant and associates with autonomic dysfunction. 38
31345232 2019
36
Dysautonomia in Guillain-Barré Syndrome: Prevalence, Clinical Spectrum, and Outcomes. 38
31297663 2019
37
Autonomic Dysfunction in Guillain-Barré Syndrome Puts Patients at Risk. 38
31338746 2019
38
Effects of inspiratory muscle training on respiratory muscle strength, lung function, functional capacity and cardiac autonomic function in Parkinson's disease: Randomized controlled clinical trial protocol. 38
31090181 2019
39
Understanding Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and the Emerging Osteopathic Approach: A Narrative Review. 38
31233110 2019
40
Impaired cardiac autonomic response in lung transplant patients: A retrospective cohort study. 38
31132178 2019
41
Small vessel disease pathological changes in neurodegenerative and vascular dementias concomitant with autonomic dysfunction. 38
31357238 2019
42
Intramedullary Spinal Cord Ganglioglioma Presenting as Hyperhidrosis: A Rare Case Report and Literature Review. 38
30904797 2019
43
Acquired cardiac channelopathies in epilepsy: Evidence, mechanisms, and clinical significance. 38
31353444 2019
44
Longitudinal assessment of autonomic dysfunction in early Parkinson's disease. 38
31320275 2019
45
Cardiovascular autonomic dysfunction, altered sleep architecture, and muscle overactivity during nocturnal sleep in pediatric patients with narcolepsy type 1. 38
31353416 2019
46
Polypharmacy in Parkinson's disease: risks and benefits with little evidence. 38
31222606 2019
47
Cardiac autonomic dysfunctions are recovered with vitamin D replacement in apparently healthy individuals with vitamin D deficiency. 38
31339201 2019
48
Epilepsy and ultra-structural heart changes: The role of catecholaminergic toxicity and myocardial fibrosis. What can we learn from cardiology? 38
31306872 2019
49
Guidelines for the conduct of clinical trials in spinal cord injury: Neuroimaging biomarkers. 38
31267015 2019
50
Central Noradrenergic Agonists in the Treatment of Ischemic Stroke-an Overview. 38
31327133 2019

Variations for Autonomic Dysfunction

Expression for Autonomic Dysfunction

Search GEO for disease gene expression data for Autonomic Dysfunction.

Pathways for Autonomic Dysfunction

Pathways related to Autonomic Dysfunction according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.67 SNCA SCN9A DBH
2 9.98 SLC18A2 DBH

GO Terms for Autonomic Dysfunction

Cellular components related to Autonomic Dysfunction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 9.8 SPTLC2 SPTLC1 SLC18A2 SCN9A RETREG1 ECE1
2 membrane GO:0016020 9.56 SPTLC2 SPTLC1 SNCA SLC18A2 SCN9A RETREG1
3 synaptic vesicle membrane GO:0030672 9.32 SNCA SLC18A2
4 terminal bouton GO:0043195 9.16 SNCA SLC18A2
5 serine C-palmitoyltransferase complex GO:0017059 8.62 SPTLC2 SPTLC1

Biological processes related to Autonomic Dysfunction according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.61 SNCA SLC18A2 DBH
2 response to toxic substance GO:0009636 9.55 SLC18A2 SCN9A
3 locomotory behavior GO:0007626 9.54 SLC18A2 DBH
4 post-embryonic development GO:0009791 9.52 SLC18A2 SCN9A
5 sensory perception of pain GO:0019233 9.51 SCN9A RETREG1
6 sphingolipid biosynthetic process GO:0030148 9.49 SPTLC2 SPTLC1
7 sphingolipid metabolic process GO:0006665 9.48 SPTLC2 SPTLC1
8 biosynthetic process GO:0009058 9.46 SPTLC2 SPTLC1
9 response to amphetamine GO:0001975 9.4 SLC18A2 DBH
10 ceramide biosynthetic process GO:0046513 9.37 SPTLC2 SPTLC1
11 positive regulation of receptor recycling GO:0001921 9.32 SNCA ECE1
12 sphingosine biosynthetic process GO:0046512 9.26 SPTLC2 SPTLC1
13 sphingomyelin biosynthetic process GO:0006686 9.16 SPTLC2 SPTLC1
14 positive regulation of lipophagy GO:1904504 8.96 SPTLC2 SPTLC1
15 sphinganine biosynthetic process GO:0046511 8.62 SPTLC2 SPTLC1

Molecular functions related to Autonomic Dysfunction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 copper ion binding GO:0005507 9.16 SNCA DBH
2 pyridoxal phosphate binding GO:0030170 8.96 SPTLC2 SPTLC1
3 serine C-palmitoyltransferase activity GO:0004758 8.62 SPTLC2 SPTLC1

Sources for Autonomic Dysfunction

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....